Pharmacokinetics of Metronidazole in pregnant women

Chemotherapy. 1981;27(2):73-9. doi: 10.1159/000237958.

Abstract

Pharmacokinetic characteristics of metronidazole were studied in 19 pregnant women with Trichomoniasis urogenitalis who had been hospitalized for legal abortion. All patients received 250 mg or 1.0 g metronidazole (Vagimid) per os in a single or multiple dose. Peak levels were reached 1-2 h after application. Mean serum levels of metronidazole were somewhat lower in gravidae than those in nonpregnant women. The mean elimination half-life values were 5.7 and 7.7 h after intake of 250 mg and 1.0 g metronidazole, respectively. As suggested by our pharmacokinetic results, the dosage regimen for treatment of anaerobic bacteria infection or parasitic infection in pregnant women can be the same as in nonpregnant patients.

MeSH terms

  • Blood Proteins / metabolism
  • Female
  • Humans
  • Kinetics
  • Metronidazole / metabolism*
  • Metronidazole / therapeutic use
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy
  • Pregnancy Complications, Infectious / metabolism*
  • Protein Binding
  • Trichomonas Infections / drug therapy

Substances

  • Blood Proteins
  • Metronidazole